Literature DB >> 1489186

Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.

H Mattie1, B A Sekh, M L van Ogtrop, E van Strijen.   

Abstract

The efficacies of cefepime and ceftazidime in an experimental Escherichia coli infection in granulocytopenic mice were related to their in vitro activities and their pharmacokinetic profiles. Cefepime had a higher intrinsic activity in vitro than ceftazidime, and it had a different pharmacokinetic profile, resulting in higher peak concentrations in plasma and a longer elimination half-life. To predict the antibacterial efficacy in vivo on the basis of in vitro activity and pharmacokinetics, we applied a mathematical model in which the in vitro effect is expressed as the difference in growth rate between control cultures and cultures grown in the presence of the antibiotic (ER), whereas the in vivo effect is given by the difference in the number of CFU between controls and antibiotic-treated animals (EN). The integral of ER over time, called ERt, was calculated by using in vivo concentrations. A significant linear relationship was found between EN and ERt for different doses at various times up to 4 h after administration, although the slope of this relationship was slightly but significantly less for cefepime (0.44) than for ceftazidime (0.59).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489186      PMCID: PMC284349          DOI: 10.1128/AAC.36.11.2439

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Authors:  R H Barbhaiya; S T Forgue; C R Gleason; C A Knupp; K A Pittman; D J Weidler; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection.

Authors:  W E Peetermans; J J Hoogeterp; A M Hazekamp-van Dokkum; P van den Broek; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.

Authors:  H Mattie; A M van Dokkum; L Brus-Weijer; A M Krul; E van Strijen
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

4.  The relation between plasma and tissue concentrations of antibiotics. Description of a method.

Authors:  H Mattie; J J Hoogeterp; J Hermans
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

5.  Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli.

Authors:  M W Kunst; H Mattie
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

6.  High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Authors:  R H Barbhaiya; S T Forgue; W C Shyu; E A Papp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  G P Bodey; D H Ho; B LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

8.  The relative potency of amoxycillin and ampicillin in vitro and in vivo.

Authors:  H Mattie; G B van der Voet
Journal:  Scand J Infect Dis       Date:  1981
  8 in total
  9 in total

1.  Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.

Authors:  Maria J Melchers; Anita C van Mil; Claudia Lagarde; Jan den Hartigh; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Pharmacokinetic and pharmacodynamic models of antimicrobial drugs in vitro and in vivo.

Authors:  H Mattie
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

3.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.

Authors:  Soon-Ee Cheah; Jian Li; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

Review 5.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment.

Authors:  Asher Brauner; Ofer Fridman; Orit Gefen; Nathalie Q Balaban
Journal:  Nat Rev Microbiol       Date:  2016-04       Impact factor: 60.633

6.  Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.

Authors:  Fabian Bernhard; Rajesh Odedra; Sylvie Sordello; Rossella Cardin; Samantha Franzoni; Cédric Charrier; Adam Belley; Peter Warn; Matthias Machacek; Philipp Knechtle
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

7.  In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

8.  Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection.

Authors:  H Mattie; L C Zhang; E van Strijen; B R Sekh; A E Douwes-Idema
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

9.  In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.

Authors:  Kamilia Abdelraouf; Safa Almarzoky Abuhussain; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.